Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9927442 | 0.87 | KMT2A (0.78) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL12878224 | 0.85 | MEN1 (0.74) | MEN1KMT2APKMALDH1A1SMN1; SMN2 | |
| SCHEMBL789616 | 0.83 | KEAP1 (0.72) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL11674303 | 0.83 | MEN1 (0.70) | MEN1KMT2APKMALDH1A1SMN1; SMN2 | |
| SCHEMBL7580127 | 0.81 | KMT2A (0.68) | MEN1KMT2APKMALDH1A1SMN1; SMN2 | |
| SCHEMBL28450939 | 0.81 | MEN1 (0.68) | MEN1KMT2APKMALDH1A1SMN1; SMN2 | |
| SCHEMBL3380247 | 0.81 | POLB (0.68) | MEN1KMT2AALDH1A1HTTMAPT | |
| SCHEMBL7571620 | 0.80 | POLB (0.68) | MEN1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL7572319 | 0.80 | POLB (0.68) | MEN1KMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL11775883 | 0.80 | MEN1 (0.66) | MEN1KMT2APKMALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | claimed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | claimed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | claimed |
| US-7989498-B2 | Immunosuppressants; autoimmune disease; organs transplantation; antiinflammatory agents; viricides; antiproliferative agents; antitumor, anticancer agents | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989498-B2 | Immunosuppressants; autoimmune disease; organs transplantation; antiinflammatory agents; viricides; antiproliferative agents; antitumor, anticancer agents | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | MEN1 1377/4885KMT2A 800/4885PKM 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.